Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Cell Medica is committed to improving patients’ lives through the significant therapeutic potential of cellular immunotherapy. Our approach is to apply innovative technologies with the aim of improving the treatment of cancer and immune reconstitution following hematopoietic stem cell transplant.

About Us

Our News

Keep upto date with our regular news and updated on all our research and product launches

Cell Medica announces the appointment of Luis Borges, PhD, as Chief Scientific Officer

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Read More...

Cell Medica acquires WT1 cancer immunotherapy from Cell and Gene Therapy Catapult

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Read More...

£60 million Series C financing to advance multiple cancer programmes

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Read More...

Lead cancer immunotherapy candidate receives FDA fast track designation

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Read More...

Cell Medica and Baylor College of Medicine expand partnership to develop allogeneic CAR-NKT cells for cancer treatment

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Read More...

Cell Medica and UCL collaborate to develop modified T cell receptor products for the treatment of cancer

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for cancer and infectious diseases.

Read More...
More News Posts